Developing practice guidelines for the administration of intravenous immunoglobulin

Journal of Infusion Nursing

Volumn 28, Issue 4, 2005, Pages 265-272

  Murphy, Elyse ^a   Martin, Sarah ^b   Patterson, Jardiolyn Valino ^c  

^a ZLB Behring   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; BLOOD DERIVATIVE; CARIMUNE NF; CORTICOSTEROID; DIPHENHYDRAMINE; FLEBAGAMMA; GAMMAGARD S/D; GAMMAR PIV; HUMAN IMMUNOGLOBULIN; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PANGLOBULIN NF; PARACETAMOL; STEROID; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ARTHRALGIA; ASEPTIC MENINGITIS; BACKACHE; BREATHING DISORDER; CHILL; COMORBIDITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG SAFETY; FEVER; FLU LIKE SYNDROME; FLUSHING; HEADACHE; HIGH RISK POPULATION; HUMAN; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTHERAPY; INFUSION; INJECTION SITE REACTION; MALAISE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NURSING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TACHYCARDIA; THORAX PAIN; THROMBOEMBOLISM; THROMBOSIS; VOMITING;

EID: 23044504754     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200507000-00009     Document Type: Review

References (43)

1. Bruton OC. Aggammaglobulinemia. Pediatrics. 1952;9:722-728.
2. Chapel H, Griffiths H, Brennan V, et al. Hypogammaglobulinemia in low-grade B cell tumours: significance and therapy. Immun Invest. 1991;20:187-191.
3. Griffiths H, Lea J, Bunch C, et al. Predictors of infection in chronic lymphocyticleukemia (CLL). Clin Exp Immunol. 1992;89:374-377.
4. Sullivan KM. Immunoglobulin therapy in bone marrow transplantation. Am J Med. 1987;83:34-45.
5. Glinz W, Grob PJ, Nydegger UE, et al. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma: a randomized, placebo-controlled study. Intensive Care Med. 1985;11:288-294.
6. Benorini TE, Nance AM, Horner LA, et al. Complications of intravenous gammaglobulins in neuromuscular and other diseases. Muscle Nerve. 1996;19:388-391.
7. Siegel J. Intravenous immune globulins: therapeutic, pharmaceutical, and cost considerations. Pharmacy Practice News. 2000 (5 Suppl):66-68.
8. Mendelsohn C, Riley P. IGIV Fundamentals for home care and alternate site therapy. Infusion. 2003;Nov/Dec:35-38.
9. Sacher RA. Intravenous immunoglobulin consensus statement. IVIG Advisory Panel. J Allergy Clin Immunol. 2002;109:1001-1004.
10. Eijkout HN, Van Der Meer JW, Kallenberg CG, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized double-blind multicenter crossover trial. Ann Intern Med. 2001;135:165-174.
11. Steihm ER, Casillas AM, Finkelstein JZ, et al. Slow subcutaneous human intravenous immunoglobulin in treatment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clin Immunol. 1998;101:848-849.
12. Gardulf A, Anderson V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345:365-369.
13. Imbach P, Barandum S, d'Apuzzo V, et al. High-dose intravenous gamma globulin for idiopathic thrombocytopenia purpura in childhood. Lancet. 1981;1:1228-1231.
14. Imbach P, Wagner HP, Berchold W, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenia purpura in childhood. Lancet. 1985;2:464-468.
15. Koski CL. Therapy of CIDP and related immune-mediated neuropathies. Neurology. 2002;59:S22-S27.
16. Dalakas MC, Fujii M, Li M, et al. High-dose intravenous immune globulin for stiff person syndrome. N Engl J Med. 1996;345:1870-1876.
17. Wiles CM, Brown P, Chapel H, et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry. 2002;72:440-448.
18. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993-2000.
19. Koski CL. Identifying the benefits if intravenous immunoglobulin in peripheral neuromuscular disease. Adv Immunother. 2004;11:9-14.
20. Dalakas M. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular disease: evidence based indications and safety profile. Pharmacology & Therapeutics. 2004;102:177-193.
21. Benorini TE, Nance AM, Horner LA, et al. Complications of intravenous gamaglobulins in neuromuscular and other diseases. Muscle Nerve. 1996;19:388-391.
22. Ratko TA. Technology Assessment: Intravenous Immune Globulin Preparations. Oak Brook, 111: University Healthsystem Consortium; 1999.
23. ASHP Commission on Therapeutics. ASHP therapeutic guidelines for intravenous immune globulin. Clin Pharm. 1992;11:117-136.
24. Grabenstein JD. Immunofacts: Vaccines and Immunologic Drugs. St. Louis: Facts and Comparisons; 2001.
25. Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin. Drug Saf. 1999;21:171-185.
26. Dicato M, Duhem C, Ries F. Nonviral side effects of intravenous immunoglobulins. In: Lee ML, Strand V, eds. Intravenous Immunoglobulins in Clinical Practice. New York: Marcel Dekker; 1997:57-65.
27. Cunningham-Rundles C. Immunoglobulin treatment in immunodeficiency diseases. In: Rich RR, Fleisher TA, Shearer WT, Kotzin BL, Schroeder HW, eds. Clinical Immunology Principles and Practice. 2nd ed. London: Mosby; 2001:103.1-.11.
28. McEvoy GK, ed. AHFS Drug Information. Bethesda: American Society of Health-System Pharmacists; 2004:3154-3163.
29. Bagdasarian A, Tonetta S, Harel W, Mamidi R, Uemura Y. IVIG adverse reactions: potential role of cytokines and vasoactive substances. Vox Sang. 1998;74:74-82.
30. Steihm R, Ochs H, Winkelstein J. Immunologic Disorders in Infants and Children. 5th ed. Philadelphia: Elsevier Saunders; 2004:332-340.
31. Grillo JA, Gorson KC, Ropper AH, et al. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology. 2001;57:1699-1701.
32. Stangel M, Hartung H-P, Marx P, Gold R. Side effects of high-dose intravenous immunoglobulins. Clin Neuropharmacol. 1997;20:385-393.
33. de Albuquerque Campos R, Sato MN, da Silva Duarte AJ. IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol. 2000;20:77-82.
34. Björkander J, Hammarströn L, Edvard Smith CI, Bukley RH, Cunningham-Rundles C, Hanson LA. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IGA antibodies. J Clin Immunol. 1987;7:8-15.
35. Renal insufficiency and failure associated with immune globulin intravenous therapy - United States, 1985-1999. MMWR Morb Mortal Wkly Rep. 1999;48(24):518-521.
36. Epstein JS, Zoon KC. Acute renal failure associated with immune globulin intravenous. ("Dear Doctor" letter). Bethesda, Md: Center for Biologics Evaluation and Research, FDA; September 24, 1999.
37. Pierce L, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev. 2003;17(4):241-251.
38. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259-262.
39. Jolles S, Hill H. Management of aseptic meningitis secondary to intravenous immunoglobulin (letter). BMJI. 1998;316:936.
40. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44:223-226.
41. Nydegger U, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf. 1999;21:171-185.
42. Wolberg AS, Kon RH, Monroe DM, et al. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol. 2000;65:30-34.
43. Peerschke E. IVIG, Platelets and Complement: Ingredients for Thrombosis? Corporate Friday Symposium at the 2003 American Society of Hematology Annual Meeting, December 5, 2003.